RCS - Creo Medical Group - First use of Speedboat® UltraSlim in Latin America

Creo MedicalAnnouncement

10/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240110:nRSJ1671Za&default-theme=true

RNS Number : 1671Z  Creo Medical Group PLC  10 January 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

First use of Speedboat® UltraSlim in Latin America

12 patients treated in three days

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that its latest device,
Speedboat® UltraSlim, has now been successfully used in Latin America for the
first time.

 

Speedboat® UltraSlim was used at the Ecuadorian Institute of Digestive
Diseases ("IECED") in late December, where Dr Carlos Robles Medranda, Dr
Michel Kahaleh and Dr Eduardo Albeniz, supported by the Creo clinical team,
performed 12 procedures using Speedboat® UltraSlim over three days, as well
as performing the first ever F-POEM procedure with the device. F-POEM
(Endoscopic Fundoplication Peroral Endoscopic Myotomy) is a minimally invasive
endoscopic procedure used to treat oesophageal motility disorders in patients
who are prone to gastroesophageal reflux.

 

Following the limited market release of Speedboat® UltraSlim in December 2023
the device has been successfully used in multiple clinical applications and
was used in the UK, USA to treat precancerous lesions in the colon, oesophagus
and stomach, in addition to performing oesophageal and gastric POEM procedures
(a procedure which addresses swallowing disorders and gastroparesis).

 

Carlos Robles-Medranda, Head of the Endoscopy Service at IECED, said: "I had
the privilege of hosting these distinguished physicians, facilitating the
successful execution of 12 procedures over three days using Speedboat
UltraSlim. The excitement around the device was noticeable, and we eagerly
anticipate the positive impact it will have on enhancing our patient pathways
as we look to address an increased number of cases."

 

Dr Michel Kahaleh, who performed many of these procedures at IECED, commented:
"From the very first time when I saw the device, I knew that it was born to do
POEM procedures. It allowed me to glide over the muscularis when tunnelling.
Once you have acquired the knowledge to use this technology, you're really
going to save procedure time. The technology allows the endoscopist to
complete an F-POEM procedure with a single device, whereas previously it
required three different devices."

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "The
procedures done at IECED have shown the full potential of the new Speedboat
UltraSlim. We were thrilled to witness the successful execution of the F-POEM
procedure using solely the Speedboat device, a task that traditionally
requires three separate instruments. This not only showcases the device's
efficiency but also enhances the cost-effectiveness of the procedure,
underscoring the economic advantages Creo's technology can deliver to our
valued customers."

 

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

About Speedboat® UltraSlim

Speedboat® UltraSlim is the third device in Creo's Speedboat® family of
products, and is targeting the therapeutic treatment of disease in the GI
tract (including cancer of the Bowel, Stomach and Oesophagus) as well as
surgical procedures to deal with abnormalities resulting in swallowing
disorders and, in some cases, gastric reflux. This latest generation Speedboat
has broad application in the GI tract due to a smaller configuration, ensuring
compatibility with a wide range of colonoscopes and gastroscopes.

 

Powered by Creo's CROMA advanced energy platform, Speedboat® UltraSlim
delivers fluid as well as advanced bipolar RF energy for controlled cutting
and high frequency MW energy for controlled coagulation of tissue in the GI
tract. The device is the culmination of a long programme of work to further
miniaturise Creo's technology, and is compatible with the working channel of
all commercially available endoscopes accessing the vast majority of GI
endoscopic procedures.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUAUGUPCPPB